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Introduction Methods 
Conclusions 
We hypothesized that CoQ10 and CoQ1 would improve post-
reperfused cardiac contractile function and reduce infarct size when 
compared to I/R control with/without drug solvent. 
Our results indicate that CoQ1 was more effective than CoQ10 in 
restoring post-reperfused cardiac contractile function, but not infarct 
size during MI/R. These differences may be attributed to CoQ1’s 
stronger antioxidant effects.  
Results 
Isolated Rat Heart MI/R Experiments:  Langendorff heart preparation 
was performed after anesthesia of male Sprague Dawley rats (275-325 
g, Charles River, Springfield MA).  Hearts were isolated and 
retrogradely perfused with Krebs’ buffer at a constant pressure of 80 
mmHg with 37°C and pH of 7.35-7.45 by aerating with 95% O2/5% 
CO2 to get the baseline of cardiac parameters. After 15 min of baseline 
perfusion, the heart was put through global ischemia by stopping 
perfusion for 30 min, followed by reperfusion for 45 min.  Krebs’ buffer 
alone, 0.2% DMSO alone (0.2% DMSO was used to solubilize CoQ1 
and CoQ10), CoQ1 (20 µM), or CoQ10 (20 µM) was infused with 1 
ml/min for the first 5 min of reperfusion.  The pressure transducer 
(SPR-524, Millar Instruments, Inc., Houston, TX) was inserted into the 
left ventricle to record left ventricular end systolic pressure (LVESP), 
left ventricular end diastolic pressure (LVEDP), maximal rate of left 
ventricular systolic pressure over time (dP/dtmax), minimal rate of left 
ventricular diastolic pressure over time (dP/dtmin) and heart rate. 
Coronary flow was measured by a flow probe which was placed in line 
with perfusion line. Data was recorded using a Powerlab Station 
acquisition system (ADInstruments, Grand Junction, CO) every 5 min 
during the baseline and reperfusion.   
Determination of Infarct size: At the end of the experiments, the left 
ventricle of the hearts were sectioned into 2 mm thick slices that were 
subjected to 1% triphenyltetrazolium chloride (TTC) staining to detect 
infarcted (unstained) and viable (stained brick red) area.  Infarct size 
was expressed as the percentage of infarcted tissue weight to the total 
tissue weight. 
Statistical Analysis: All data in the figures are presented as means ± 
S.E.M. The data was analyzed by analysis of variance using post hoc 
analysis with Fisher’s PLSD test. p<0.05 are considered to be 
statistically significant.  
Hypothesis 
Acute myocardial infarction (MI) is a major cause of morbidity and 
mortality worldwide.  The goal of therapy is to limit the irreversible cell 
damage via quick reperfusion.  However, the restoration of blood flow 
to a prolonged ischemic area (MI/R) per se can induce additional 
cardiac damage [1].  Currently, there are no effective treatments to 
mitigate this reperfusion induced injury.  Oxidative stress, 
characterized as the rapid production of reactive oxygen species, has 
been indicated to mediate MI/R injury.  Mitochondria may be a principle 
source of oxidative stress causing MI/R injury. Coenzyme Q10 
(CoQ10) is essential for electron transport chain (ETC) in normal 
mitochondria. It accepts the electron generated from complex I or II to 
form its reduced form, ubiquinol; then donates the electron to complex 
III to return its oxidized form, ubiquinone (see figure 1). The 
bioavailability of CoQ10 is likely reduced during MI/R, which can 
interrupt the electron transport via ETC, and then free electrons may 
bind to oxygen to generate superoxide during early reperfusion and 
attribute to the oxidative stress [2]. CoQ10 also has antioxidant 
properties and has been used as an adjunctive agent in the treatment 
of cardiovascular disease, such as congestive heart failure and 
hypertension [3]. Coenzyme Q1 (CoQ1) is a derivative of CoQ10, but 
is a more potent antioxidant than CoQ10 due to a shorter isoprene 
chain (see figure 2) [4]. This study tested the effects of CoQ10 and 
CoQ1 on postreperfused cardiac function and infarct size in an 
isolated rat MI/R model.  
 
Figure 1. The role of CoQ10 in electron transport chain in mitochondria. CoQ10 will 
transport electron between the conversion of its oxidized form (e.g., ubiquinone) and reduced 
form (e.g., ubiquinol). (adapted from 2012 Pearson education, Inc). 
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Figure 2. The chemical structure of 
CoQ10 and CoQ1. CoQ10  has the 
1,4-benzoquinone chemical group 
with 10 isoprenyl subunits in its tail.  
By contrast, CoQ1 only has 1 
isoprenyl subunit in its tail.  
Figure 3. Time course of LVDP for Sham, MI/R, MI/R+ DMSO, MI/R + 20 µM CoQ1, MI/R + 
20 µM CoQ10 groups.   LVDP is the difference between LVESP and LVEDP. Control MI/R and 
MI/R + DMSO exhibited significantly lower post-reperfused LVDP compared to the Sham.  By 
contrast, application of 20 µM CoQ1 significantly improved post-reperfused LVDP, which was 
significantly higher compared to the untreated MI/R controls and the effects of 20 µM CoQ10 
treatment. (* p< 0.05, ** p< 0.01 vs. MI/R and MI/R + DMSO; # p< 0.05 vs. MI/R + 20 µM 
CoQ10) 
Figure 4. Time course of dP/dtmax for Sham, MI/R, MI/R+ DMSO, MI/R + 20 µM CoQ1, MI/R 
+ 20 µM CoQ10 groups. Control MI/R and MI/R + DMSO exhibited significantly lower post-
reperfused dP/dtmax compared to the Sham.  By contrast, application of 20 µM CoQ1 
significantly improved post-reperfused dP/dtmax, which was significantly higher compared to 
the untreated MI/R controls and the effects of 20 µM CoQ10 treatment. (* p< 0.05, ** p< 0.01 
vs. MI/R and MI/R + DMSO; # p< 0.05 vs. MI/R + 20 µM CoQ10) 
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Figure 5. The representative TTC 
staining pictures and summarized 
infarct size graph for experimental 
groups. Sham, CoQ1, and CoQ10 
groups exhibited significantly lower 
infarct size compared to the MI/R 
group. (** p< 0.01 vs. MI/R) 
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